{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T05:57:00Z","timestamp":1769579820318,"version":"3.49.0"},"reference-count":60,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T00:00:00Z","timestamp":1564099200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>The introduction of new targeted, biological, and cellular therapies in patients with hematologic malignancies has improved the outcomes of patients but in parallel has changed the frequency and epidemiology of infections, including invasive aspergillosis (IA). In this article, recent literature on the epidemiology and clinical findings of IA in patients who have lymphoproliferative and myeloproliferative diseases and are undergoing novel targeted treatment with kinase inhibitors, agents targeting cell surface antigens, chimeric antigen receptor-modified T cells, and antibodies to immune checkpoint molecules is reviewed and the clinical impact of IA on the overall management of the underlying disease is discussed. Overall, IA represents a variable and uncommon complication in these populations, but given the increasing eligibility criteria of these novel treatments (particularly in patients with relapsed or refractory hematologic malignancies) and the prolonged periods of therapy, a considerable number of unusual cases of <ns4:italic>Aspergillus<\/ns4:italic> infections can be expected in clinical practice.<\/ns4:p>","DOI":"10.12688\/f1000research.17836.1","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T10:35:06Z","timestamp":1564137306000},"page":"1202","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies"],"prefix":"10.12688","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3245-2357","authenticated-orcid":false,"given":"Corrado","family":"Girmenia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2019,7,26]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"662-72","DOI":"10.1055\/s-0035-1562893","article-title":"Invasive Aspergillosis: Epidemiology, Clinical Aspects, and Treatment.","volume":"36","author":"K Gregg","year":"2015","journal-title":"Semin Respir Crit Care Med."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"727-35","DOI":"10.1093\/cid\/ciy181","article-title":"Epidemiology and Outcomes of Hospitalizations With Invasive Aspergillosis in the United States, 2009-2013.","volume":"67","author":"M Zilberberg","year":"2018","journal-title":"Clin Infect Dis."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"550-62","DOI":"10.1016\/j.jinf.2018.02.012","article-title":"The burden of Invasive Aspergillosis in patients with haematological malignancy: A meta-analysis and systematic review.","volume":"76","author":"R van de Peppel","year":"2018","journal-title":"J Infect."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"17-29","DOI":"10.1016\/j.blre.2016.09.002","article-title":"Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations.","volume":"31","author":"L Pagano","year":"2017","journal-title":"Blood Rev."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"644-50","DOI":"10.3324\/haematol.2009.012054","article-title":"Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study.","volume":"95","author":"L Pagano","year":"2010","journal-title":"Haematologica."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"872-80","DOI":"10.1016\/j.bbmt.2014.03.004","article-title":"Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO).","volume":"20","author":"C Girmenia","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"990-6","DOI":"10.1111\/j.1469-0691.2011.03685.x","article-title":"New category of probable invasive pulmonary aspergillosis in haematological patients.","volume":"18","author":"C Girmenia","year":"2012","journal-title":"Clin Microbiol Infect."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"531-6","DOI":"10.1016\/j.ijantimicag.2010.08.010","article-title":"The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and\/or immunosuppressed patients.","volume":"36","author":"S Perkhofer","year":"2010","journal-title":"Int J Antimicrob Agents."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"1882-9","DOI":"10.1111\/j.1469-0691.2011.03548.x","article-title":"Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007).","volume":"17","author":"O Lortholary","year":"2011","journal-title":"Clin Microbiol Infect."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"141-51","DOI":"10.1007\/s15010-013-0539-3","article-title":"SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients.","volume":"42","author":"M Montagna","year":"2014","journal-title":"Infection."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1200\/JCO.2018.36.15_suppl.1568","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 2006 to 2016: A systematic analysis for the Global Burden of Disease study.","volume":"36","author":"C Fitzmaurice","year":"2018","journal-title":"JCO."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"1844-8","DOI":"10.3109\/10428194.2013.853299","article-title":"Invasive fungal infections in lymphoproliferative disorders: a monocentric retrospective experience.","volume":"55","author":"A Nosari","year":"2014","journal-title":"Leuk Lymphoma."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"3221-3230","DOI":"10.1093\/jac\/dky286","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia.","volume":"73","author":"J Maertens","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"S53-S70","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).","volume":"24 Suppl 2","author":"M Reinwald","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"S83-S94","DOI":"10.1016\/j.cmi.2018.03.022","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4).","volume":"24 Suppl 2","author":"L Drgona","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"S71-S82","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52).","volume":"24 Suppl 2","author":"M Mikulska","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"S21-S40","DOI":"10.1016\/j.cmi.2018.02.002","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).","volume":"24 Suppl 2","author":"K Winthrop","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"S95-S107","DOI":"10.1016\/j.cmi.2018.01.030","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).","volume":"24 Suppl 2","author":"G Redelman-Sidi","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41409-019-0451-2","article-title":"Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)\u2013an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).","volume":"379","author":"A Kansagra","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"193-202","DOI":"10.1097\/01.md.0000229482.27398.ad","article-title":"X-linked agammaglobulinemia: report on a United States registry of 201 patients.","volume":"85","author":"J Winkelstein","year":"2006","journal-title":"Medicine (Baltimore)."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"e94496","DOI":"10.1371\/journal.pone.0094496","article-title":"Identification of a role for the PI3K\/AKT\/mTOR signaling pathway in innate immune cells.","volume":"9","author":"S Xie","year":"2014","journal-title":"PLoS One."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"240-58","DOI":"10.15252\/emmm.201404556","article-title":"Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus.","volume":"7","author":"S Herbst","year":"2015","journal-title":"EMBO Mol Med."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"1985-8","DOI":"10.1182\/blood-2017-12-823393","article-title":"Ibrutinib blocks Btk-dependent NF-\u0138B and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis.","volume":"132","author":"A Bercusson","year":"2018","journal-title":"Blood."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"625-32","DOI":"10.1080\/10428194.2017.1347931","article-title":"Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.","volume":"59","author":"A Williams","year":"2018","journal-title":"Leuk Lymphoma."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"55-68","DOI":"10.4137\/BMI.S22430","article-title":"Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors.","volume":"10","author":"M Reinwald","year":"2016","journal-title":"Biomark Insights."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"2062-7","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.","volume":"125","author":"P Jain","year":"2015","journal-title":"Blood."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"687-92","DOI":"10.1093\/cid\/ciy175","article-title":"Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.","volume":"67","author":"T Varughese","year":"2018","journal-title":"Clin Infect Dis."},{"key":"ref-28","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0481-1","article-title":"Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies.","author":"K Rogers","year":"2019","journal-title":"Leukemia."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"1955-9","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.","volume":"131","author":"D Ghez","year":"2018","journal-title":"Blood."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"833-843.e5","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.","volume":"31","author":"M Lionakis","year":"2017","journal-title":"Cancer Cell."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"3390-7","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia.","volume":"123","author":"J Brown","year":"2014","journal-title":"Blood."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"2686-94","DOI":"10.1182\/blood-2015-03-630947","article-title":"A phase 2 study of idelalisib plus rituximab in treatment-na\u00efve older patients with chronic lymphocytic leukemia.","volume":"126","author":"S O'Brien","year":"2015","journal-title":"Blood."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"997-1007","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia.","volume":"370","author":"R Furman","year":"2014","journal-title":"N Engl J Med."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"e114-e126","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.","volume":"4","author":"J Jones","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"297-311","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: Interim results from a phase 3, randomised, double-blind, placebo-controlled trial.","volume":"18","author":"A Zelenetz","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"293-6","DOI":"10.1016\/j.medmal.2016.10.001","article-title":"Sequential disseminated aspergillosis and pulmonary tuberculosis in a patient treated by idelalisib for chronic lymphocytic leukemia.","volume":"47","author":"B Lafon-Desmurs","year":"2017","journal-title":"Med Mal Infect."},{"key":"ref-37","article-title":"Efficacy results of a phase 2 trial evaluating idelalisib plus ofatumumab in patients with previously untreated chronic lymphocytic leukemia, #1734","author":"B Lampson","year":"2017"},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"311-22","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.","volume":"374","author":"A Roberts","year":"2016","journal-title":"N Engl J Med."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"768-78","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: A multicentre, open-label, phase 2 study.","volume":"17","author":"S Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"4371-9","DOI":"10.1158\/1078-0432.CCR-17-3761","article-title":"Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia.","volume":"24","author":"M Davids","year":"2018","journal-title":"Clin Cancer Res."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"915-20","DOI":"10.1080\/17474086.2018.1548931","article-title":"Venetoclax for the treatment of multiple myeloma.","volume":"11","author":"I Vaxman","year":"2018","journal-title":"Expert Rev Hematol."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"e441-e444","DOI":"10.1016\/j.clml.2018.07.289","article-title":"Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia.","volume":"18","author":"J El-Cheikh","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"7-17","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.","volume":"133","author":"C DiNardo","year":"2019","journal-title":"Blood."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"1417-1421","DOI":"10.3324\/haematol.2018.204958","article-title":"Targeting BCL2 with venetoclax is a promising therapeutic strategy for \"double-proteinexpression\" lymphoma with MYC and BCL2 rearrangements.","volume":"104","author":"A Uchida","year":"2018","journal-title":"Haematologica."},{"key":"ref-45","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1025","article-title":"Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.","author":"J Fishman","year":"2018","journal-title":"Clin Infect Dis."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"64-73","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy.","volume":"379","author":"C June","year":"2018","journal-title":"N Engl J Med."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"439-48","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.","volume":"378","author":"S Maude","year":"2018","journal-title":"N Engl J Med."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"1875-84","DOI":"10.1158\/1078-0432.CCR-15-1433","article-title":"Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy.","volume":"22","author":"M Maus","year":"2016","journal-title":"Clin Cancer Res."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"449-59","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.","volume":"378","author":"J Park","year":"2018","journal-title":"N Engl J Med."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"45-56","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.","volume":"380","author":"S Schuster","year":"2019","journal-title":"N Engl J Med."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"31-42","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.","volume":"20","author":"F Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"533-40","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.","volume":"67","author":"J Park","year":"2018","journal-title":"Clin Infect Dis."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"121-130","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.","volume":"131","author":"J Hill","year":"2018","journal-title":"Blood."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers.","volume":"50","author":"P Darvin","year":"2018","journal-title":"Exp Mol Med."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"30-42","DOI":"10.3324\/haematol.2016.150656","article-title":"The emerging role of immune checkpoint inhibition in malignant lymphoma.","volume":"102","author":"I Hude","year":"2017","journal-title":"Haematologica."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"390-6","DOI":"10.1182\/asheducation-2016.1.390","article-title":"Checkpoint inhibition and cellular immunotherapy in lymphoma.","volume":"2016","author":"P Lulla","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"ref-57","first-page":"45-55","article-title":"Checkpoint inhibition in lymphoma.","volume":"16","author":"G Shah","year":"2018","journal-title":"Clin Adv Hematol Oncol."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"1052-68","DOI":"10.1016\/j.immuni.2016.04.022","article-title":"Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.","volume":"44","author":"J Attanasio","year":"2016","journal-title":"Immunity."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S1473-3099(16)30541-2","article-title":"Nivolumab plus interferon-\u03b3 in the treatment of intractable mucormycosis.","volume":"17","author":"D Grimaldi","year":"2017","journal-title":"Lancet Infect Dis."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"1571-3","DOI":"10.1016\/S1470-2045(17)30852-5","article-title":"Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis.","volume":"18","author":"N Daver","year":"2017","journal-title":"Lancet Oncol."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/8-1202\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-1202\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-1202\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T10:50:07Z","timestamp":1564138207000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/8-1202\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,26]]},"references-count":60,"URL":"https:\/\/doi.org\/10.12688\/f1000research.17836.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.19501.r51690","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.19501.r51689","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.19501.r51679","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,26]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/8-1202\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.19501.r51679, David S. Perlin, Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA, 26 Jul 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1202\/v1#referee-response-51679","order":0,"name":"referee-response-51679","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.19501.r51689, Marcio Nucci, Department of Internal Medicine, University Hospital, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 26 Jul 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1202\/v1#referee-response-51689","order":1,"name":"referee-response-51689","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.19501.r51690, Russell E Lewis, Clinic of Infectious Diseases, Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy, 26 Jul 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1202\/v1#referee-response-51690","order":2,"name":"referee-response-51690","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Data associated with the article are available under the terms of the Creative Commons Zero \"No rights reserved\" data waiver (CC0 1.0 Public domain dedication).","order":0,"name":"copyright-info","label":"Copyright"}]}}